General Neurology
Prognosis after cardiac arrest
Jan. 15, 2024
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.
Roman numbers indicate nomenclature for muscle glycogenoses: numerals in color orange for glycogenoses causing rhabdomyolysis, in green color for those causing fixed weakness. Glycogenoses types: 0, glycogen synthase; II, acid maltase (GAA, Pompe disease); III, debrancher (GDE, Cori-Forbes disease); IV, brancher (GBE, Andersen disease); V, myophosphorylase (PYGM, McArdle disease); VII, phosphofructokinase (PFK, Tarui disease); IX, phosphorylase kinase (PHK); phosphoglycerate kinase (PGK); X, phosphoglycerate mutase (PGAM); XI, lactate dehydrogenase (LDH); XII, aldolase A; XIII, β-enolase; XIV, phosphoglucomutase (PGM); XV, glycogenin. Abbreviations: UDPG, uridine diphosphate glucose; PLD, phosphorylase limit dextrin. (Contributed by Dr. Ezequiel A Piccione.)